Treating Hyperexcitability in AD With Levetiracetam

Inclusion Criteria: Inclusion Criteria for the Subjects with early Alzheimer's Disease (AD) * Age 50-90 years old. * On a stable dose of medications for memory loss including cholinesterase inhibitors (for example: donepezil, rivastigmine or memantine) as defined by 4 consecutive weeks of treatment at an unchanging dose * Meeting the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD. * Mini Mental State Examination (MMSE) ≥ 20. * Positive amyloid status (as defined by cerebral spinal fluid biomarkers or amyloid positron emission tomography (PET) study. * Clinician Dementia Rating (CDR) of 0.5-1.0. Inclusion Criteria for Healthy Control Subjects * Age 50-90 years old. * Normal neurologic exam * Mini Mental State Examination (MMSE) \> 28 * Clinician Dementia Rating (CDR) of 0 Exclusion Criteria: Exclusion Criteria Subjects with early Alzheimer's Disease * Diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist. Evidence of epileptiform discharges and electroencephalogram (EEG) abnormalities will be included; * Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke (cortical stroke), progressive neurologic disease (e.g. multiple sclerosis) or intracra…